8.4 C
Munich

Walmart latest pharmacy chain to propose to settle lawsuits with govts

Must read

[ad_1]


Retail giant on Tuesday become the latest major player in the drug industry to announce a plan to settle lawsuits filed by state and local governments over the toll of powerful prescription opioids sold at its pharmacies with state and local governments across the US.


The USD 3.1 billion proposal follows similar announcements November 2 from the two largest US chains, CVS Health and Walgreen Co., which each said they would pay about USD 5 billion.


The deals are the product of negotiations with a group of state attorneys general, but they are not final. The CVS and Walgreens deals would have to be accepted first by a critical mass of state and local governments before they are completed.


Walmart’s plan would have to be approved by 43 states. The formal process has not yet begun.


The national pharmacies join some of the biggest drugmakers and drug distributors in settling complex lawsuits over their alleged roles in an opioid overdose epidemic that has been linked to more than 500,000 deaths in the US over the past two decades.


The tally of proposed and finalised settlements in recent years is more than USD 50 billion, with most of that to be used by governments to combat the crisis.


In the 2000s, most fatal opioid overdoses involved prescription drugs such as OxyContin and generic oxycodone. After governments, doctors and took steps to make them harder to obtain, people addicted to the drugs increasingly turned to heroin, which proved more deadly.


In recent years, opioid deaths have soared to record levels around 80,000 a year. Most of those deaths involve illicitly produced version of the powerful lab-made drug fentanyl, which is appearing throughout the US supply of illegal drugs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

[ad_2]

Source link

- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article